NSRX logo

NASUS PHARMA LTD

NSRXNYSE AMERICAN
๐Ÿ† #4446 by market capUS Equity
โ€”โ€”
Quote unavailable
๐Ÿ””
Track NSRX
Get earnings, price moves & breaking news on Telegram
Track
24hโ€”
7dโ€”
14dโ€”
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$27M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
โ€”
๐Ÿ“ŠGross Margin
โ€”
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
โ€”
Otter Score
โ€”
Insufficient data
No chart data available for NSRX.

Trading Snapshot

Day Range
โ€”
52-Week Range
$1.98 โ€“ $9.50
Volume (shares)
โ€”
Avg Volume (shares)
โ€”
Shares Outstanding
11.7M
Next Earnings
โ€”

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
โ€”
P/S Ratio
โ€”
EPS (TTM)
$-0.87
Dividend Yield
โ€”
NSRX logo

NASUS PHARMA LTD

NSRX
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About NASUS PHARMA LTD

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.